TransMedics Group, Inc. Common Stock
TMDX
$74.77
+0.65%
TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy for end-stage organ failure patients. Its core innovation is the Organ Care System (OCS), a portable perfusion and monitoring platform designed to preserve donor organs in a near-physiologic state, addressing the significant limitations of traditional cold storage. The company has established itself as a disruptive leader in the medical device sector, specifically within organ preservation. The current investor narrative is heavily centered on the company's rapid commercial execution and path to sustained profitability, as evidenced by its recent transition to GAAP profitability, though recent stock price volatility suggests ongoing debate about its valuation and growth sustainability amidst a broader market rotation.…
TMDX
TransMedics Group, Inc. Common Stock
$74.77
Investment Opinion: Should I buy TMDX Today?
Rating & Thesis: Based on the synthesis of strong fundamentals against severe technical and sentiment headwinds, the recommendation is a HOLD. The core thesis is that TransMedics is a fundamentally sound, high-growth company caught in a vicious market-driven sell-off, making it too risky to buy aggressively here but too strong to sell outright. Analyst sentiment, while lacking a consensus price target, leans bullish with several reiterated Buy ratings.
Supporting Evidence: The stock trades at a forward P/E of 20.1x, which is reasonable for a company delivering 32.2% YoY revenue growth. Operating fundamentals are strengthening, with gross margin at 59.9% and the generation of $133.6M in TTM free cash flow. The valuation has compressed dramatically from a trailing P/E of 76.4x a year ago to 21.7x today, suggesting significant pessimism is already priced in. The company's return on equity of 40.2% indicates highly efficient capital use.
Risks & Conditions: The two biggest risks are 1) continued high-beta volatility and momentum selling pushing the stock below its $60.11 support, and 2) a deceleration in revenue growth or operating margin compression. This Hold would upgrade to a Buy if the stock establishes a firm technical base above $70 and shows sequential revenue acceleration in the next quarter, or if the forward P/E compresses further toward 15x. It would downgrade to a Sell if revenue growth decelerates below 20% or if operating margins contract significantly. Relative to its own history, the stock appears fairly valued to slightly undervalued, but versus the broader market's risk-off sentiment, it remains vulnerable.
Sign up to view all
TMDX 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The fundamental picture is robust, characterized by high growth, improving profitability, and a strong financial position. However, the technical and sentiment backdrop is dire, with the stock in a severe downtrend, exhibiting high volatility (beta 2.06), and facing significant short interest. The current valuation appears fair for the growth profile, but momentum is a powerful opposing force. The stance would upgrade to bullish on a confirmed technical reversal above $80 coupled with sustained operating margin expansion. It would turn bearish if the stock breaks below $60 support on high volume, signaling a failure of the current consolidation attempt.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransMedics Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $97.20 and implied upside of +30.0% versus the current price.
Average Target
$97.20
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$60 - $97
Analyst target range
Analyst coverage for TMDX appears limited, with only 5 analysts providing estimates for revenue and EPS, though the institutional ratings list shows activity from 10 distinct firms. The consensus sentiment leans bullish, with recent actions including reiterated 'Buy', 'Outperform', and 'Overweight' ratings from firms like Needham, Oppenheimer, and Piper Sandler, alongside 'Hold' or 'Neutral' stances from Stifel and JP Morgan. Specific consensus price targets and an implied upside/downside calculation cannot be derived from the provided data, which lacks average target price figures. The target price range is also not specified in the data. The high target would likely assume continued market penetration, margin expansion, and successful execution of the company's national OCS program. The low target would factor in risks such as increased competition, reimbursement challenges, or a slowdown in transplant procedure volumes. The recent institutional ratings show a pattern of reaffirmation rather than major changes following the Q4 2025 earnings report in late February 2026, suggesting analysts are in a 'wait-and-see' mode to confirm the sustainability of the profitability trend before making significant rating adjustments.
Bulls vs Bears: TMDX Investment Factors
The bull case, centered on explosive fundamental growth, strong cash generation, and a compressed valuation, is compelling but currently overshadowed by severe technical damage and negative market sentiment. The bear side currently has stronger evidence in the near term, as reflected in the stock's 45% annual decline, high short interest, and momentum deeply diverging from the market. The single most important tension in the investment debate is whether the company's robust 32% revenue growth and path to sustainable operating profitability can overcome the intense selling pressure and valuation de-rating driven by broader market rotations away from high-beta, high-multiple stocks. The resolution hinges on the next few quarters of execution proving the Q4 profitability was not a fluke.
Bullish
- Explosive Revenue Growth & Profitability: Q4 2025 revenue grew 32.2% YoY to $160.8M, marking a sequential climb from $143.5M in Q1 2025, demonstrating robust commercial traction. The company achieved GAAP profitability with a net margin of 65.5% in Q4, supported by a 59.9% gross margin and 17.9% operating margin, showing scalable operations.
- Strong Cash Flow & Balance Sheet: The company generated $133.6M in trailing free cash flow, providing ample internal capital for growth. A current ratio of 7.14 indicates exceptional short-term liquidity, and a debt-to-equity of 0.99 is manageable for a growth-stage medtech firm.
- Valuation Compression to Attractive Levels: The trailing P/E of 21.73x represents a dramatic de-rating from highs of 76.36x in Q4 2024 and 39.35x in Q3 2025. This places the valuation at the lower end of its own historical range, potentially pricing in excessive pessimism given the strong fundamentals.
- High Capital Efficiency: Return on Equity of 40.2% is exceptionally high, signaling efficient use of shareholder capital. This is driven by the combination of strong profitability and a leveraged balance sheet, a positive sign for future returns.
Bearish
- Severe Technical Downtrend & High Volatility: The stock is down 45% over the past year and 44.9% over the last three months, underperforming the SPY by over 57 percentage points in 3 months. With a beta of 2.061, the stock is more than twice as volatile as the market, amplifying downside risk during sell-offs.
- Profitability Boosted by One-Time Tax Benefit: Q4 2025 net income of $105.4M was significantly inflated by an $83.8M income tax benefit. Excluding this, operating income was $21.3M, indicating the core business profitability, while strong, is not as elevated as the headline net margin suggests.
- High Short Interest & Negative Momentum: A short ratio of 4.91 indicates significant bearish sentiment and potential for continued selling pressure. The stock is trading just 18.8% above its 52-week low of $60.11, reflecting a lack of buyer conviction and risk of further declines.
- Valuation Multiples Remain Elevated: Despite the compression, a trailing P/E of 21.7x and a P/S ratio of 6.8x are not cheap for a single-product medical device company. This leaves room for further multiple contraction if growth decelerates or market sentiment sours further on growth stocks.
TMDX Technical Analysis
The prevailing price trend for TMDX is a severe and sustained downtrend, with the stock down 45.02% over the past year and trading near the lows of its 52-week range. With a current price of $71.37, it sits just 18.8% above its 52-week low of $60.105, indicating the stock is in deeply oversold territory and facing significant selling pressure, which presents a potential value opportunity but also the risk of catching a 'falling knife' if negative sentiment persists. Recent momentum shows extreme acceleration to the downside, with the stock plummeting 44.93% over the past three months and 24.82% in the last month alone, far underperforming the SPY's gains of 12.6% and 4.6% over the same periods, respectively. This severe short-term weakness, diverging from a market rally, signals capitulation selling and a potential washout, though a definitive reversal signal has yet to emerge. Key technical levels are clear: immediate support is the 52-week low of $60.105, while formidable resistance lies at the 52-week high of $156.0. A breakdown below $60 would likely trigger another leg down, whereas a sustained move above recent highs near $75 could signal a stabilization attempt. The stock's beta of 2.061 confirms it is more than twice as volatile as the market, which amplifies both downside risk and potential upside during a recovery, necessitating careful risk management for investors.
Beta
1.88
1.88x market volatility
Max Drawdown
-58.8%
Largest decline past year
52-Week Range
$60-$156
Price range past year
Annual Return
-46.9%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | +16.3% | -1.9% |
| 3m | -38.4% | +8.9% |
| 6m | -41.0% | +6.4% |
| 1y | -46.9% | +20.3% |
| ytd | -39.1% | +6.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
TransMedics is demonstrating explosive revenue growth, with Q4 2025 revenue of $160.8 million representing a 32.2% year-over-year increase. This growth is part of a strong multi-quarter trend, as revenue has climbed sequentially from $143.5 million in Q1 2025, indicating robust commercial adoption of its OCS technology. The company's product segment, representing its entire revenue stream, is the sole driver of this expansion, underscoring the focused success of its core offering. Profitability has dramatically improved, with the company reporting net income of $105.4 million and a net margin of 65.5% in Q4 2025, though this was significantly aided by a substantial income tax benefit of $83.8 million. Excluding this, operating fundamentals are strengthening, with gross margin at a healthy 59.9% and operating margin of 17.9%, showing the business is scaling efficiently toward sustainable profitability from an operating perspective. The balance sheet and cash flow position are robust, supporting future growth. The company boasts a strong current ratio of 7.14 and a manageable debt-to-equity ratio of 0.99. Most importantly, it generated $133.6 million in trailing twelve-month free cash flow, providing ample internal funding for operations and expansion. The return on equity of 40.2% is exceptionally high, reflecting efficient use of shareholder capital, though it is partially inflated by the recent large net income figure.
Quarterly Revenue
$160764000.0B
2025-12
Revenue YoY Growth
+0.32%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$133589000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. TMDX trades at a trailing PE of 21.73x and a forward PE of 20.09x, based on estimated EPS. The minimal gap between trailing and forward multiples suggests the market expects earnings growth to be roughly in line with the current run-rate, implying a stabilization after the recent profit surge. Compared to sector averages, specific industry comparison data is not available in the provided dataset, preventing a quantified premium/discount analysis. However, a trailing PE in the low 20s for a high-growth medical technology company with recent GAAP profitability could be considered reasonable if growth expectations remain high. Historically, the stock's own valuation has compressed significantly. Its current trailing PE of 21.73x is far below its historical highs seen in recent quarters, such as 39.35x in Q3 2025 and 76.36x in Q4 2024. This sharp de-rating places the valuation near the lower end of its own recent historical range, suggesting the market has priced in a more conservative outlook or a normalization after a period of excessive optimism, potentially creating a value entry point if fundamentals remain strong.
PE
21.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -683x~311x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: While profitability has improved, the Q4 2025 net income was heavily skewed by an $83.8M one-time tax benefit; core operating income was $21.3M, representing a 13.2% operating margin. The company's revenue is 100% concentrated in its Organ Care System, making it vulnerable to any product-specific clinical, reimbursement, or supply chain issue. Although free cash flow is positive at $133.6M TTM, the high beta of 2.061 implies earnings and cash flow are perceived as volatile and highly sensitive to market cycles.
Market & Competitive Risks: The stock's valuation, while compressed from its highs, still carries a forward P/E of 20.1x and a P/S of 6.8x, leaving it exposed to further multiple compression if growth stock sentiment deteriorates. The severe underperformance versus the SPY (down 45% vs. SPY up 27% over one year) indicates the market is pricing in significant sector-specific or company-specific risks, potentially including increased competition or regulatory scrutiny. The high short ratio of 4.91 reflects a crowded bearish trade that could exacerbate downside moves on any negative news.
Worst-Case Scenario: A combination of slowing revenue growth below 20%, a miss on operating margin targets, and a broader market sell-off triggering de-rating of high-beta stocks could unfold. This could lead to a re-test and break below the 52-week low of $60.11, potentially targeting levels implied by a further compression of the P/E multiple towards 15x. From the current price of $71.37, a realistic worst-case downside to the $50-$55 range (a 25-30% decline) is plausible, aligning with a max drawdown that has already approached -59%.
FAQ
The key risks are, in order of severity: 1) Market & Sentiment Risk: The stock's high beta (2.06) and severe underperformance (-45% vs. SPY +27% over 1 year) make it highly susceptible to further selling in a risk-off environment. 2) Execution & Growth Risk: Revenue is 100% dependent on the OCS platform; any slowdown in adoption or competitive threat could derail the growth narrative. 3) Valuation Risk: Despite the compression, the P/E of 21.7x leaves room for further de-rating if growth decelerates. 4) Profitability Risk: The recent GAAP profit was boosted by a large one-time tax benefit; investors need to see sustainable operating profitability in upcoming quarters.
TMDX appears fairly valued to slightly undervalued relative to its own growth profile but remains vulnerable to broader market sentiment. At a forward P/E of 20.1x and a P/S of 6.8x, the valuation has compressed dramatically from a trailing P/E of 76.4x a year ago. For a company growing revenue over 30% with improving margins, these multiples are not excessive. However, without a clear sector peer comparison, the valuation is largely judged on its own history, where it sits at the lower end. The market is currently pricing in a significant slowdown in growth or multiple compression, creating a potential disconnect with the still-strong fundamentals.
TMDX presents a high-risk, high-reward opportunity. For investors with a high risk tolerance and a long-term horizon, the current price may represent a compelling entry point after a 45% decline, given the company's strong 32% revenue growth and path to profitability. However, the severe technical downtrend, high beta of 2.06, and significant short interest make it a volatile and risky buy in the near term. It is a good buy only for those who believe the fundamental growth story remains intact and are prepared for potential further downside volatility before a recovery.
TMDX is unsuitable for short-term trading due to its extreme volatility (beta 2.06) and lack of a clear near-term catalyst for a swift reversal. It is a speculative long-term investment for investors with a 3-5 year horizon who can withstand significant drawdowns. The company is in a capital-intensive growth phase (no dividend) with high earnings visibility only on a quarterly basis. The investment thesis is based on multi-year adoption of its OCS technology; therefore, a minimum holding period of 2-3 years is suggested to allow the fundamental story to play out and overcome near-term sentiment and volatility headwinds.
